nodes	percent_of_prediction	percent_of_DWPC	metapath
Bimatoprost—AKR1C3—Doxorubicin—urinary bladder cancer	0.603	1	CbGbCtD
Bimatoprost—PTGER3—prostate gland—urinary bladder cancer	0.0148	0.101	CbGeAlD
Bimatoprost—PTGFR—prostate gland—urinary bladder cancer	0.0118	0.081	CbGeAlD
Bimatoprost—PTGER1—renal system—urinary bladder cancer	0.0115	0.0788	CbGeAlD
Bimatoprost—PTGER3—smooth muscle tissue—urinary bladder cancer	0.0105	0.0717	CbGeAlD
Bimatoprost—PTGER3—renal system—urinary bladder cancer	0.0101	0.0691	CbGeAlD
Bimatoprost—AKR1C3—prostate gland—urinary bladder cancer	0.00961	0.0658	CbGeAlD
Bimatoprost—PTGER1—female reproductive system—urinary bladder cancer	0.00921	0.0631	CbGeAlD
Bimatoprost—AKR1C3—Podofilox—Etoposide—urinary bladder cancer	0.00914	1	CbGdCrCtD
Bimatoprost—PTGFR—smooth muscle tissue—urinary bladder cancer	0.00837	0.0574	CbGeAlD
Bimatoprost—AKR1C3—seminal vesicle—urinary bladder cancer	0.00813	0.0557	CbGeAlD
Bimatoprost—PTGER3—female reproductive system—urinary bladder cancer	0.00807	0.0553	CbGeAlD
Bimatoprost—PTGFR—urethra—urinary bladder cancer	0.00792	0.0542	CbGeAlD
Bimatoprost—AKR1C3—smooth muscle tissue—urinary bladder cancer	0.0068	0.0466	CbGeAlD
Bimatoprost—PTGFR—female reproductive system—urinary bladder cancer	0.00645	0.0442	CbGeAlD
Bimatoprost—AKR1C3—urethra—urinary bladder cancer	0.00643	0.0441	CbGeAlD
Bimatoprost—Dinoprost Tromethamine—HPGDS—urinary bladder cancer	0.00533	0.472	CrCbGaD
Bimatoprost—AKR1C3—vagina—urinary bladder cancer	0.00474	0.0325	CbGeAlD
Bimatoprost—PTGER3—lymph node—urinary bladder cancer	0.00472	0.0324	CbGeAlD
Bimatoprost—Dinoprostone—HPGDS—urinary bladder cancer	0.0041	0.363	CrCbGaD
Bimatoprost—PTGFR—lymph node—urinary bladder cancer	0.00378	0.0259	CbGeAlD
Bimatoprost—AKR1C3—lymph node—urinary bladder cancer	0.00307	0.021	CbGeAlD
Bimatoprost—Tafluprost—PTGS2—urinary bladder cancer	0.00186	0.165	CrCbGaD
Bimatoprost—AKR1C3—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—urinary bladder cancer	0.00129	0.122	CbGpPWpGaD
Bimatoprost—AKR1C3—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.000874	0.0826	CbGpPWpGaD
Bimatoprost—Skin discolouration—Epirubicin—urinary bladder cancer	0.000773	0.00351	CcSEcCtD
Bimatoprost—Headache—Mitomycin—urinary bladder cancer	0.000771	0.0035	CcSEcCtD
Bimatoprost—Inflammation—Methotrexate—urinary bladder cancer	0.000769	0.0035	CcSEcCtD
Bimatoprost—Cough increased—Epirubicin—urinary bladder cancer	0.000763	0.00347	CcSEcCtD
Bimatoprost—Erythema—Thiotepa—urinary bladder cancer	0.000758	0.00345	CcSEcCtD
Bimatoprost—Lacrimation increased—Epirubicin—urinary bladder cancer	0.000758	0.00344	CcSEcCtD
Bimatoprost—Sinusitis—Fluorouracil—urinary bladder cancer	0.000753	0.00342	CcSEcCtD
Bimatoprost—Tension—Thiotepa—urinary bladder cancer	0.000744	0.00338	CcSEcCtD
Bimatoprost—Nervousness—Thiotepa—urinary bladder cancer	0.000736	0.00335	CcSEcCtD
Bimatoprost—Rhinitis—Gemcitabine—urinary bladder cancer	0.000734	0.00334	CcSEcCtD
Bimatoprost—Nausea—Mitomycin—urinary bladder cancer	0.000731	0.00332	CcSEcCtD
Bimatoprost—Cystitis noninfective—Methotrexate—urinary bladder cancer	0.000729	0.00331	CcSEcCtD
Bimatoprost—Pharyngitis—Gemcitabine—urinary bladder cancer	0.000727	0.00331	CcSEcCtD
Bimatoprost—Rhinitis—Fluorouracil—urinary bladder cancer	0.000722	0.00328	CcSEcCtD
Bimatoprost—Oedema peripheral—Gemcitabine—urinary bladder cancer	0.000722	0.00328	CcSEcCtD
Bimatoprost—Cystitis—Methotrexate—urinary bladder cancer	0.00072	0.00328	CcSEcCtD
Bimatoprost—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.00072	0.00327	CcSEcCtD
Bimatoprost—Inflammation—Epirubicin—urinary bladder cancer	0.00072	0.00327	CcSEcCtD
Bimatoprost—Skin discolouration—Doxorubicin—urinary bladder cancer	0.000715	0.00325	CcSEcCtD
Bimatoprost—Pharyngitis—Fluorouracil—urinary bladder cancer	0.000715	0.00325	CcSEcCtD
Bimatoprost—Vision blurred—Thiotepa—urinary bladder cancer	0.000714	0.00325	CcSEcCtD
Bimatoprost—Cough increased—Doxorubicin—urinary bladder cancer	0.000706	0.00321	CcSEcCtD
Bimatoprost—Lacrimation increased—Doxorubicin—urinary bladder cancer	0.000701	0.00319	CcSEcCtD
Bimatoprost—Cystitis noninfective—Epirubicin—urinary bladder cancer	0.000682	0.0031	CcSEcCtD
Bimatoprost—Bladder pain—Methotrexate—urinary bladder cancer	0.000674	0.00307	CcSEcCtD
Bimatoprost—Cystitis—Epirubicin—urinary bladder cancer	0.000674	0.00306	CcSEcCtD
Bimatoprost—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.000671	0.00305	CcSEcCtD
Bimatoprost—Inflammation—Doxorubicin—urinary bladder cancer	0.000666	0.00303	CcSEcCtD
Bimatoprost—Angiopathy—Gemcitabine—urinary bladder cancer	0.000664	0.00302	CcSEcCtD
Bimatoprost—Cough—Thiotepa—urinary bladder cancer	0.000661	0.00301	CcSEcCtD
Bimatoprost—Mediastinal disorder—Gemcitabine—urinary bladder cancer	0.00066	0.003	CcSEcCtD
Bimatoprost—Visual impairment—Cisplatin—urinary bladder cancer	0.000658	0.00299	CcSEcCtD
Bimatoprost—Hypertension—Thiotepa—urinary bladder cancer	0.000654	0.00298	CcSEcCtD
Bimatoprost—Dry eye—Epirubicin—urinary bladder cancer	0.000645	0.00293	CcSEcCtD
Bimatoprost—Anxiety—Thiotepa—urinary bladder cancer	0.000643	0.00292	CcSEcCtD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000641	0.00291	CcSEcCtD
Bimatoprost—Eye disorder—Cisplatin—urinary bladder cancer	0.000638	0.0029	CcSEcCtD
Bimatoprost—Erythema—Gemcitabine—urinary bladder cancer	0.000638	0.0029	CcSEcCtD
Bimatoprost—Bladder pain—Epirubicin—urinary bladder cancer	0.000631	0.00287	CcSEcCtD
Bimatoprost—Cystitis noninfective—Doxorubicin—urinary bladder cancer	0.000631	0.00287	CcSEcCtD
Bimatoprost—Erythema—Fluorouracil—urinary bladder cancer	0.000627	0.00285	CcSEcCtD
Bimatoprost—Cystitis—Doxorubicin—urinary bladder cancer	0.000624	0.00284	CcSEcCtD
Bimatoprost—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.000615	0.0028	CcSEcCtD
Bimatoprost—Infection—Thiotepa—urinary bladder cancer	0.000615	0.00279	CcSEcCtD
Bimatoprost—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000607	0.00276	CcSEcCtD
Bimatoprost—Skin disorder—Thiotepa—urinary bladder cancer	0.000601	0.00273	CcSEcCtD
Bimatoprost—Dry eye—Doxorubicin—urinary bladder cancer	0.000597	0.00271	CcSEcCtD
Bimatoprost—Erythema—Cisplatin—urinary bladder cancer	0.000594	0.0027	CcSEcCtD
Bimatoprost—Vision blurred—Fluorouracil—urinary bladder cancer	0.000591	0.00269	CcSEcCtD
Bimatoprost—Eye disorder—Etoposide—urinary bladder cancer	0.000584	0.00266	CcSEcCtD
Bimatoprost—Bladder pain—Doxorubicin—urinary bladder cancer	0.000584	0.00266	CcSEcCtD
Bimatoprost—Visual disturbance—Methotrexate—urinary bladder cancer	0.000571	0.0026	CcSEcCtD
Bimatoprost—Angiopathy—Etoposide—urinary bladder cancer	0.000567	0.00258	CcSEcCtD
Bimatoprost—Mediastinal disorder—Etoposide—urinary bladder cancer	0.000564	0.00256	CcSEcCtD
Bimatoprost—Eye pain—Epirubicin—urinary bladder cancer	0.000561	0.00255	CcSEcCtD
Bimatoprost—Vision blurred—Cisplatin—urinary bladder cancer	0.00056	0.00255	CcSEcCtD
Bimatoprost—Cough—Gemcitabine—urinary bladder cancer	0.000556	0.00253	CcSEcCtD
Bimatoprost—Hypertension—Gemcitabine—urinary bladder cancer	0.00055	0.0025	CcSEcCtD
Bimatoprost—Somnolence—Thiotepa—urinary bladder cancer	0.00055	0.0025	CcSEcCtD
Bimatoprost—Dyspepsia—Thiotepa—urinary bladder cancer	0.000544	0.00248	CcSEcCtD
Bimatoprost—Chest pain—Gemcitabine—urinary bladder cancer	0.000543	0.00247	CcSEcCtD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000539	0.00245	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000534	0.00243	CcSEcCtD
Bimatoprost—Chest pain—Fluorouracil—urinary bladder cancer	0.000534	0.00243	CcSEcCtD
Bimatoprost—Pain—Thiotepa—urinary bladder cancer	0.000529	0.00241	CcSEcCtD
Bimatoprost—Eye pain—Doxorubicin—urinary bladder cancer	0.000519	0.00236	CcSEcCtD
Bimatoprost—Infection—Gemcitabine—urinary bladder cancer	0.000517	0.00235	CcSEcCtD
Bimatoprost—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00051	0.00232	CcSEcCtD
Bimatoprost—Infection—Fluorouracil—urinary bladder cancer	0.000508	0.00231	CcSEcCtD
Bimatoprost—Diplopia—Epirubicin—urinary bladder cancer	0.000507	0.0023	CcSEcCtD
Bimatoprost—Skin disorder—Gemcitabine—urinary bladder cancer	0.000505	0.0023	CcSEcCtD
Bimatoprost—Anxiety—Cisplatin—urinary bladder cancer	0.000504	0.00229	CcSEcCtD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000502	0.00228	CcSEcCtD
Bimatoprost—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000502	0.00228	CcSEcCtD
Bimatoprost—Liver function test abnormal—Methotrexate—urinary bladder cancer	0.0005	0.00227	CcSEcCtD
Bimatoprost—Vertigo—Etoposide—urinary bladder cancer	0.000489	0.00222	CcSEcCtD
Bimatoprost—Infection—Cisplatin—urinary bladder cancer	0.000482	0.00219	CcSEcCtD
Bimatoprost—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000476	0.00216	CcSEcCtD
Bimatoprost—Cough—Etoposide—urinary bladder cancer	0.000475	0.00216	CcSEcCtD
Bimatoprost—Skin disorder—Cisplatin—urinary bladder cancer	0.000471	0.00214	CcSEcCtD
Bimatoprost—Insomnia—Gemcitabine—urinary bladder cancer	0.000471	0.00214	CcSEcCtD
Bimatoprost—Hypertension—Etoposide—urinary bladder cancer	0.00047	0.00214	CcSEcCtD
Bimatoprost—Diplopia—Doxorubicin—urinary bladder cancer	0.000469	0.00213	CcSEcCtD
Bimatoprost—Asthma—Methotrexate—urinary bladder cancer	0.000468	0.00213	CcSEcCtD
Bimatoprost—Liver function test abnormal—Epirubicin—urinary bladder cancer	0.000468	0.00213	CcSEcCtD
Bimatoprost—AKR1C3—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000465	0.0439	CbGpPWpGaD
Bimatoprost—Dry skin—Epirubicin—urinary bladder cancer	0.000464	0.00211	CcSEcCtD
Bimatoprost—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000464	0.00211	CcSEcCtD
Bimatoprost—Chest pain—Etoposide—urinary bladder cancer	0.000464	0.00211	CcSEcCtD
Bimatoprost—Insomnia—Fluorouracil—urinary bladder cancer	0.000463	0.0021	CcSEcCtD
Bimatoprost—Somnolence—Gemcitabine—urinary bladder cancer	0.000463	0.0021	CcSEcCtD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00046	0.00209	CcSEcCtD
Bimatoprost—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000456	0.00207	CcSEcCtD
Bimatoprost—Somnolence—Fluorouracil—urinary bladder cancer	0.000455	0.00207	CcSEcCtD
Bimatoprost—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.000453	0.00206	CcSEcCtD
Bimatoprost—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00045	0.00205	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000449	0.00204	CcSEcCtD
Bimatoprost—AKR1C3—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—urinary bladder cancer	0.000448	0.0424	CbGpPWpGaD
Bimatoprost—Pain—Gemcitabine—urinary bladder cancer	0.000445	0.00202	CcSEcCtD
Bimatoprost—Asthenia—Thiotepa—urinary bladder cancer	0.000444	0.00202	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000442	0.00201	CcSEcCtD
Bimatoprost—Infection—Etoposide—urinary bladder cancer	0.000441	0.00201	CcSEcCtD
Bimatoprost—Asthma—Epirubicin—urinary bladder cancer	0.000438	0.00199	CcSEcCtD
Bimatoprost—Pruritus—Thiotepa—urinary bladder cancer	0.000438	0.00199	CcSEcCtD
Bimatoprost—Pain—Fluorouracil—urinary bladder cancer	0.000438	0.00199	CcSEcCtD
Bimatoprost—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000435	0.00198	CcSEcCtD
Bimatoprost—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.000433	0.00197	CcSEcCtD
Bimatoprost—Dyspnoea—Cisplatin—urinary bladder cancer	0.000432	0.00197	CcSEcCtD
Bimatoprost—Skin disorder—Etoposide—urinary bladder cancer	0.000432	0.00196	CcSEcCtD
Bimatoprost—Dry skin—Doxorubicin—urinary bladder cancer	0.00043	0.00195	CcSEcCtD
Bimatoprost—Bronchitis—Epirubicin—urinary bladder cancer	0.000421	0.00192	CcSEcCtD
Bimatoprost—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000419	0.00191	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000419	0.0019	CcSEcCtD
Bimatoprost—Depression—Methotrexate—urinary bladder cancer	0.000416	0.00189	CcSEcCtD
Bimatoprost—Pain—Cisplatin—urinary bladder cancer	0.000415	0.00189	CcSEcCtD
Bimatoprost—AKR1C3—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000411	0.0388	CbGpPWpGaD
Bimatoprost—Dizziness—Thiotepa—urinary bladder cancer	0.000409	0.00186	CcSEcCtD
Bimatoprost—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000407	0.00185	CcSEcCtD
Bimatoprost—Asthma—Doxorubicin—urinary bladder cancer	0.000405	0.00184	CcSEcCtD
Bimatoprost—Dyspnoea—Etoposide—urinary bladder cancer	0.000396	0.0018	CcSEcCtD
Bimatoprost—Somnolence—Etoposide—urinary bladder cancer	0.000395	0.0018	CcSEcCtD
Bimatoprost—Rash—Thiotepa—urinary bladder cancer	0.00039	0.00177	CcSEcCtD
Bimatoprost—Bronchitis—Doxorubicin—urinary bladder cancer	0.00039	0.00177	CcSEcCtD
Bimatoprost—Dermatitis—Thiotepa—urinary bladder cancer	0.00039	0.00177	CcSEcCtD
Bimatoprost—AKR1C3—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00039	0.0368	CbGpPWpGaD
Bimatoprost—Headache—Thiotepa—urinary bladder cancer	0.000388	0.00176	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000384	0.00174	CcSEcCtD
Bimatoprost—Pain—Etoposide—urinary bladder cancer	0.00038	0.00173	CcSEcCtD
Bimatoprost—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000377	0.00171	CcSEcCtD
Bimatoprost—Asthenia—Gemcitabine—urinary bladder cancer	0.000373	0.0017	CcSEcCtD
Bimatoprost—Pharyngitis—Methotrexate—urinary bladder cancer	0.000372	0.00169	CcSEcCtD
Bimatoprost—Pruritus—Gemcitabine—urinary bladder cancer	0.000368	0.00167	CcSEcCtD
Bimatoprost—Nausea—Thiotepa—urinary bladder cancer	0.000367	0.00167	CcSEcCtD
Bimatoprost—Sinusitis—Epirubicin—urinary bladder cancer	0.000366	0.00167	CcSEcCtD
Bimatoprost—Pruritus—Fluorouracil—urinary bladder cancer	0.000362	0.00165	CcSEcCtD
Bimatoprost—Visual impairment—Methotrexate—urinary bladder cancer	0.000361	0.00164	CcSEcCtD
Bimatoprost—AKR1C3—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000356	0.0337	CbGpPWpGaD
Bimatoprost—Rhinitis—Epirubicin—urinary bladder cancer	0.000351	0.0016	CcSEcCtD
Bimatoprost—Eye disorder—Methotrexate—urinary bladder cancer	0.00035	0.00159	CcSEcCtD
Bimatoprost—Asthenia—Cisplatin—urinary bladder cancer	0.000348	0.00158	CcSEcCtD
Bimatoprost—Pharyngitis—Epirubicin—urinary bladder cancer	0.000348	0.00158	CcSEcCtD
Bimatoprost—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000345	0.00157	CcSEcCtD
Bimatoprost—PTGER3—Prostaglandin Synthesis and Regulation—PTGS2—urinary bladder cancer	0.000345	0.0326	CbGpPWpGaD
Bimatoprost—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000345	0.00157	CcSEcCtD
Bimatoprost—Angiopathy—Methotrexate—urinary bladder cancer	0.00034	0.00155	CcSEcCtD
Bimatoprost—Sinusitis—Doxorubicin—urinary bladder cancer	0.000339	0.00154	CcSEcCtD
Bimatoprost—Dizziness—Fluorouracil—urinary bladder cancer	0.000338	0.00154	CcSEcCtD
Bimatoprost—Visual impairment—Epirubicin—urinary bladder cancer	0.000338	0.00154	CcSEcCtD
Bimatoprost—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000338	0.00154	CcSEcCtD
Bimatoprost—Rash—Gemcitabine—urinary bladder cancer	0.000328	0.00149	CcSEcCtD
Bimatoprost—Dermatitis—Gemcitabine—urinary bladder cancer	0.000328	0.00149	CcSEcCtD
Bimatoprost—Eye disorder—Epirubicin—urinary bladder cancer	0.000328	0.00149	CcSEcCtD
Bimatoprost—Erythema—Methotrexate—urinary bladder cancer	0.000326	0.00148	CcSEcCtD
Bimatoprost—Headache—Gemcitabine—urinary bladder cancer	0.000326	0.00148	CcSEcCtD
Bimatoprost—Rhinitis—Doxorubicin—urinary bladder cancer	0.000325	0.00148	CcSEcCtD
Bimatoprost—Rash—Fluorouracil—urinary bladder cancer	0.000323	0.00147	CcSEcCtD
Bimatoprost—Dermatitis—Fluorouracil—urinary bladder cancer	0.000322	0.00147	CcSEcCtD
Bimatoprost—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000322	0.00146	CcSEcCtD
Bimatoprost—AKR1C3—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000321	0.0303	CbGpPWpGaD
Bimatoprost—Headache—Fluorouracil—urinary bladder cancer	0.000321	0.00146	CcSEcCtD
Bimatoprost—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.00032	0.00145	CcSEcCtD
Bimatoprost—Asthenia—Etoposide—urinary bladder cancer	0.000319	0.00145	CcSEcCtD
Bimatoprost—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000319	0.00145	CcSEcCtD
Bimatoprost—Angiopathy—Epirubicin—urinary bladder cancer	0.000318	0.00145	CcSEcCtD
Bimatoprost—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000316	0.00144	CcSEcCtD
Bimatoprost—Pruritus—Etoposide—urinary bladder cancer	0.000314	0.00143	CcSEcCtD
Bimatoprost—Visual impairment—Doxorubicin—urinary bladder cancer	0.000313	0.00142	CcSEcCtD
Bimatoprost—Nausea—Gemcitabine—urinary bladder cancer	0.000309	0.00141	CcSEcCtD
Bimatoprost—Vision blurred—Methotrexate—urinary bladder cancer	0.000307	0.0014	CcSEcCtD
Bimatoprost—Rash—Cisplatin—urinary bladder cancer	0.000306	0.00139	CcSEcCtD
Bimatoprost—Dermatitis—Cisplatin—urinary bladder cancer	0.000306	0.00139	CcSEcCtD
Bimatoprost—Erythema—Epirubicin—urinary bladder cancer	0.000305	0.00139	CcSEcCtD
Bimatoprost—Nausea—Fluorouracil—urinary bladder cancer	0.000304	0.00138	CcSEcCtD
Bimatoprost—Eye disorder—Doxorubicin—urinary bladder cancer	0.000303	0.00138	CcSEcCtD
Bimatoprost—Tension—Epirubicin—urinary bladder cancer	0.000299	0.00136	CcSEcCtD
Bimatoprost—Nervousness—Epirubicin—urinary bladder cancer	0.000296	0.00135	CcSEcCtD
Bimatoprost—Angiopathy—Doxorubicin—urinary bladder cancer	0.000294	0.00134	CcSEcCtD
Bimatoprost—Dizziness—Etoposide—urinary bladder cancer	0.000294	0.00134	CcSEcCtD
Bimatoprost—Vertigo—Methotrexate—urinary bladder cancer	0.000293	0.00133	CcSEcCtD
Bimatoprost—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000292	0.00133	CcSEcCtD
Bimatoprost—Nausea—Cisplatin—urinary bladder cancer	0.000288	0.00131	CcSEcCtD
Bimatoprost—Vision blurred—Epirubicin—urinary bladder cancer	0.000288	0.00131	CcSEcCtD
Bimatoprost—Cough—Methotrexate—urinary bladder cancer	0.000285	0.00129	CcSEcCtD
Bimatoprost—Erythema—Doxorubicin—urinary bladder cancer	0.000282	0.00128	CcSEcCtD
Bimatoprost—Rash—Etoposide—urinary bladder cancer	0.00028	0.00127	CcSEcCtD
Bimatoprost—Dermatitis—Etoposide—urinary bladder cancer	0.00028	0.00127	CcSEcCtD
Bimatoprost—Headache—Etoposide—urinary bladder cancer	0.000278	0.00127	CcSEcCtD
Bimatoprost—Chest pain—Methotrexate—urinary bladder cancer	0.000278	0.00126	CcSEcCtD
Bimatoprost—Tension—Doxorubicin—urinary bladder cancer	0.000277	0.00126	CcSEcCtD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000276	0.00125	CcSEcCtD
Bimatoprost—AKR1C3—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000275	0.026	CbGpPWpGaD
Bimatoprost—Nervousness—Doxorubicin—urinary bladder cancer	0.000274	0.00125	CcSEcCtD
Bimatoprost—Vertigo—Epirubicin—urinary bladder cancer	0.000274	0.00125	CcSEcCtD
Bimatoprost—Palpitations—Epirubicin—urinary bladder cancer	0.00027	0.00123	CcSEcCtD
Bimatoprost—Cough—Epirubicin—urinary bladder cancer	0.000266	0.00121	CcSEcCtD
Bimatoprost—Vision blurred—Doxorubicin—urinary bladder cancer	0.000266	0.00121	CcSEcCtD
Bimatoprost—Infection—Methotrexate—urinary bladder cancer	0.000264	0.0012	CcSEcCtD
Bimatoprost—Nausea—Etoposide—urinary bladder cancer	0.000264	0.0012	CcSEcCtD
Bimatoprost—Hypertension—Epirubicin—urinary bladder cancer	0.000263	0.0012	CcSEcCtD
Bimatoprost—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000261	0.00119	CcSEcCtD
Bimatoprost—Chest pain—Epirubicin—urinary bladder cancer	0.00026	0.00118	CcSEcCtD
Bimatoprost—Anxiety—Epirubicin—urinary bladder cancer	0.000259	0.00118	CcSEcCtD
Bimatoprost—Skin disorder—Methotrexate—urinary bladder cancer	0.000259	0.00118	CcSEcCtD
Bimatoprost—PTGFR—Prostaglandin Synthesis and Regulation—PTGS2—urinary bladder cancer	0.000258	0.0244	CbGpPWpGaD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000258	0.00117	CcSEcCtD
Bimatoprost—Dry mouth—Epirubicin—urinary bladder cancer	0.000254	0.00116	CcSEcCtD
Bimatoprost—Vertigo—Doxorubicin—urinary bladder cancer	0.000254	0.00115	CcSEcCtD
Bimatoprost—PTGER1—Prostaglandin Synthesis and Regulation—PTGS2—urinary bladder cancer	0.000253	0.0239	CbGpPWpGaD
Bimatoprost—Palpitations—Doxorubicin—urinary bladder cancer	0.00025	0.00113	CcSEcCtD
Bimatoprost—Infection—Epirubicin—urinary bladder cancer	0.000247	0.00113	CcSEcCtD
Bimatoprost—Cough—Doxorubicin—urinary bladder cancer	0.000246	0.00112	CcSEcCtD
Bimatoprost—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000244	0.00111	CcSEcCtD
Bimatoprost—Hypertension—Doxorubicin—urinary bladder cancer	0.000244	0.00111	CcSEcCtD
Bimatoprost—Skin disorder—Epirubicin—urinary bladder cancer	0.000242	0.0011	CcSEcCtD
Bimatoprost—Insomnia—Methotrexate—urinary bladder cancer	0.000241	0.00109	CcSEcCtD
Bimatoprost—Chest pain—Doxorubicin—urinary bladder cancer	0.00024	0.00109	CcSEcCtD
Bimatoprost—Anxiety—Doxorubicin—urinary bladder cancer	0.00024	0.00109	CcSEcCtD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000239	0.00109	CcSEcCtD
Bimatoprost—Dyspnoea—Methotrexate—urinary bladder cancer	0.000237	0.00108	CcSEcCtD
Bimatoprost—Somnolence—Methotrexate—urinary bladder cancer	0.000237	0.00108	CcSEcCtD
Bimatoprost—Dry mouth—Doxorubicin—urinary bladder cancer	0.000235	0.00107	CcSEcCtD
Bimatoprost—Dyspepsia—Methotrexate—urinary bladder cancer	0.000234	0.00107	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.00023	0.00104	CcSEcCtD
Bimatoprost—Infection—Doxorubicin—urinary bladder cancer	0.000229	0.00104	CcSEcCtD
Bimatoprost—Pain—Methotrexate—urinary bladder cancer	0.000228	0.00103	CcSEcCtD
Bimatoprost—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000226	0.00103	CcSEcCtD
Bimatoprost—Insomnia—Epirubicin—urinary bladder cancer	0.000225	0.00102	CcSEcCtD
Bimatoprost—Skin disorder—Doxorubicin—urinary bladder cancer	0.000224	0.00102	CcSEcCtD
Bimatoprost—Dyspnoea—Epirubicin—urinary bladder cancer	0.000222	0.00101	CcSEcCtD
Bimatoprost—Somnolence—Epirubicin—urinary bladder cancer	0.000221	0.00101	CcSEcCtD
Bimatoprost—Dyspepsia—Epirubicin—urinary bladder cancer	0.000219	0.000997	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000215	0.000978	CcSEcCtD
Bimatoprost—AKR1C3—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000213	0.0202	CbGpPWpGaD
Bimatoprost—Pain—Epirubicin—urinary bladder cancer	0.000213	0.000968	CcSEcCtD
Bimatoprost—Insomnia—Doxorubicin—urinary bladder cancer	0.000208	0.000948	CcSEcCtD
Bimatoprost—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000205	0.000934	CcSEcCtD
Bimatoprost—Somnolence—Doxorubicin—urinary bladder cancer	0.000205	0.000932	CcSEcCtD
Bimatoprost—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000203	0.000922	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000199	0.000905	CcSEcCtD
Bimatoprost—Pain—Doxorubicin—urinary bladder cancer	0.000197	0.000896	CcSEcCtD
Bimatoprost—Asthenia—Methotrexate—urinary bladder cancer	0.000191	0.000868	CcSEcCtD
Bimatoprost—Pruritus—Methotrexate—urinary bladder cancer	0.000188	0.000856	CcSEcCtD
Bimatoprost—Asthenia—Epirubicin—urinary bladder cancer	0.000179	0.000813	CcSEcCtD
Bimatoprost—Pruritus—Epirubicin—urinary bladder cancer	0.000176	0.000801	CcSEcCtD
Bimatoprost—Dizziness—Methotrexate—urinary bladder cancer	0.000176	0.0008	CcSEcCtD
Bimatoprost—Rash—Methotrexate—urinary bladder cancer	0.000168	0.000763	CcSEcCtD
Bimatoprost—Dermatitis—Methotrexate—urinary bladder cancer	0.000168	0.000762	CcSEcCtD
Bimatoprost—Headache—Methotrexate—urinary bladder cancer	0.000167	0.000758	CcSEcCtD
Bimatoprost—Asthenia—Doxorubicin—urinary bladder cancer	0.000165	0.000752	CcSEcCtD
Bimatoprost—Dizziness—Epirubicin—urinary bladder cancer	0.000165	0.000749	CcSEcCtD
Bimatoprost—Pruritus—Doxorubicin—urinary bladder cancer	0.000163	0.000741	CcSEcCtD
Bimatoprost—AKR1C3—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000162	0.0153	CbGpPWpGaD
Bimatoprost—Nausea—Methotrexate—urinary bladder cancer	0.000158	0.000719	CcSEcCtD
Bimatoprost—Rash—Epirubicin—urinary bladder cancer	0.000157	0.000714	CcSEcCtD
Bimatoprost—Dermatitis—Epirubicin—urinary bladder cancer	0.000157	0.000713	CcSEcCtD
Bimatoprost—Headache—Epirubicin—urinary bladder cancer	0.000156	0.000709	CcSEcCtD
Bimatoprost—Dizziness—Doxorubicin—urinary bladder cancer	0.000152	0.000693	CcSEcCtD
Bimatoprost—Nausea—Epirubicin—urinary bladder cancer	0.000148	0.000673	CcSEcCtD
Bimatoprost—Rash—Doxorubicin—urinary bladder cancer	0.000145	0.000661	CcSEcCtD
Bimatoprost—Dermatitis—Doxorubicin—urinary bladder cancer	0.000145	0.00066	CcSEcCtD
Bimatoprost—Headache—Doxorubicin—urinary bladder cancer	0.000144	0.000656	CcSEcCtD
Bimatoprost—Nausea—Doxorubicin—urinary bladder cancer	0.000137	0.000622	CcSEcCtD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000125	0.0118	CbGpPWpGaD
Bimatoprost—AKR1C3—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000115	0.0108	CbGpPWpGaD
Bimatoprost—AKR1C3—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000105	0.00996	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—GSTO2—urinary bladder cancer	8.07e-05	0.00762	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—GSTZ1—urinary bladder cancer	7.13e-05	0.00673	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—GSTO2—urinary bladder cancer	6.76e-05	0.00638	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—NAT1—urinary bladder cancer	6.76e-05	0.00638	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.65e-05	0.00628	CbGpPWpGaD
Bimatoprost—PTGER3—G alpha (i) signalling events—CXCL8—urinary bladder cancer	6.45e-05	0.00609	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—SLC19A1—urinary bladder cancer	6.27e-05	0.00593	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—UGT2B7—urinary bladder cancer	6.18e-05	0.00584	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—PRSS3—urinary bladder cancer	6.11e-05	0.00578	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—HDAC4—urinary bladder cancer	5.83e-05	0.00551	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—HDAC4—urinary bladder cancer	5.78e-05	0.00546	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—CYP4B1—urinary bladder cancer	5.56e-05	0.00526	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—SLC19A1—urinary bladder cancer	5.25e-05	0.00496	CbGpPWpGaD
Bimatoprost—PTGER3—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	5.13e-05	0.00484	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—PRSS3—urinary bladder cancer	5.12e-05	0.00484	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—GLI1—urinary bladder cancer	4.85e-05	0.00458	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—LIG1—urinary bladder cancer	4.63e-05	0.00438	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—HDAC4—urinary bladder cancer	4.33e-05	0.00409	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—HDAC4—urinary bladder cancer	4.23e-05	0.004	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.11e-05	0.00388	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—TYMP—urinary bladder cancer	4.09e-05	0.00387	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—HDAC4—urinary bladder cancer	4.08e-05	0.00386	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.93e-05	0.00371	CbGpPWpGaD
Bimatoprost—PTGER3—GPCR ligand binding—CXCL8—urinary bladder cancer	3.9e-05	0.00369	CbGpPWpGaD
Bimatoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	3.83e-05	0.00362	CbGpPWpGaD
Bimatoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	3.78e-05	0.00357	CbGpPWpGaD
Bimatoprost—PTGER1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	3.75e-05	0.00354	CbGpPWpGaD
Bimatoprost—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	3.7e-05	0.0035	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—NAT2—urinary bladder cancer	3.7e-05	0.0035	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—GLI1—urinary bladder cancer	3.62e-05	0.00342	CbGpPWpGaD
Bimatoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	3.58e-05	0.00338	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—GLI1—urinary bladder cancer	3.55e-05	0.00335	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—ENO2—urinary bladder cancer	3.53e-05	0.00334	CbGpPWpGaD
Bimatoprost—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	3.5e-05	0.00331	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—GLI1—urinary bladder cancer	3.42e-05	0.00323	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—RBX1—urinary bladder cancer	3.35e-05	0.00316	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—RBX1—urinary bladder cancer	3.32e-05	0.00314	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—RRM2—urinary bladder cancer	3.2e-05	0.00302	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—TSC1—urinary bladder cancer	3.12e-05	0.00295	CbGpPWpGaD
Bimatoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	3.04e-05	0.00287	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—JAG1—urinary bladder cancer	3e-05	0.00283	CbGpPWpGaD
Bimatoprost—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	2.97e-05	0.00281	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—JAG1—urinary bladder cancer	2.97e-05	0.00281	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—HPGDS—urinary bladder cancer	2.96e-05	0.0028	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—ENO2—urinary bladder cancer	2.96e-05	0.0028	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.94e-05	0.00278	CbGpPWpGaD
Bimatoprost—PTGFR—GPCR ligand binding—CXCL8—urinary bladder cancer	2.92e-05	0.00276	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—GSTT1—urinary bladder cancer	2.87e-05	0.00271	CbGpPWpGaD
Bimatoprost—PTGER1—GPCR ligand binding—CXCL8—urinary bladder cancer	2.86e-05	0.0027	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.83e-05	0.00267	CbGpPWpGaD
Bimatoprost—PTGER3—GPCR downstream signaling—RHOA—urinary bladder cancer	2.51e-05	0.00237	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—RBX1—urinary bladder cancer	2.48e-05	0.00235	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—RBX1—urinary bladder cancer	2.43e-05	0.0023	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—S100B—urinary bladder cancer	2.41e-05	0.00227	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—NQO1—urinary bladder cancer	2.39e-05	0.00225	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—RBX1—urinary bladder cancer	2.35e-05	0.00222	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—TSC1—urinary bladder cancer	2.34e-05	0.00221	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.31e-05	0.00219	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—TSC1—urinary bladder cancer	2.29e-05	0.00216	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—RHOA—urinary bladder cancer	2.28e-05	0.00216	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—JAG1—urinary bladder cancer	2.22e-05	0.0021	CbGpPWpGaD
Bimatoprost—PTGER3—GPCR downstream signaling—CXCL8—urinary bladder cancer	2.21e-05	0.00208	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—TSC1—urinary bladder cancer	2.21e-05	0.00208	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—NCOR1—urinary bladder cancer	2.18e-05	0.00206	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—JAG1—urinary bladder cancer	2.18e-05	0.00206	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—NCOR1—urinary bladder cancer	2.16e-05	0.00204	CbGpPWpGaD
Bimatoprost—PTGER3—GPCR downstream signaling—IL2—urinary bladder cancer	2.11e-05	0.00199	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—JAG1—urinary bladder cancer	2.1e-05	0.00198	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—ERCC2—urinary bladder cancer	2.05e-05	0.00194	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.02e-05	0.00191	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—CXCL8—urinary bladder cancer	2e-05	0.00189	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—GSTP1—urinary bladder cancer	1.99e-05	0.00188	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—MTHFR—urinary bladder cancer	1.93e-05	0.00182	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.92e-05	0.00182	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—TERT—urinary bladder cancer	1.92e-05	0.00182	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—IL2—urinary bladder cancer	1.91e-05	0.00181	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—TERT—urinary bladder cancer	1.91e-05	0.0018	CbGpPWpGaD
Bimatoprost—PTGFR—GPCR downstream signaling—RHOA—urinary bladder cancer	1.88e-05	0.00178	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—TYMS—urinary bladder cancer	1.85e-05	0.00175	CbGpPWpGaD
Bimatoprost—PTGER1—GPCR downstream signaling—RHOA—urinary bladder cancer	1.84e-05	0.00174	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—GSTM1—urinary bladder cancer	1.83e-05	0.00173	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—NCOR1—urinary bladder cancer	1.83e-05	0.00173	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—S100B—urinary bladder cancer	1.8e-05	0.0017	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—FGFR3—urinary bladder cancer	1.77e-05	0.00167	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—S100B—urinary bladder cancer	1.76e-05	0.00166	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—FGFR3—urinary bladder cancer	1.75e-05	0.00165	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—GPX1—urinary bladder cancer	1.75e-05	0.00165	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—ERCC2—urinary bladder cancer	1.72e-05	0.00162	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling by GPCR—RHOA—urinary bladder cancer	1.71e-05	0.00161	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—ESR1—urinary bladder cancer	1.7e-05	0.00161	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—S100B—urinary bladder cancer	1.7e-05	0.00161	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling by GPCR—RHOA—urinary bladder cancer	1.67e-05	0.00158	CbGpPWpGaD
Bimatoprost—PTGFR—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.65e-05	0.00156	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—NCOR1—urinary bladder cancer	1.62e-05	0.00153	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—MTHFR—urinary bladder cancer	1.62e-05	0.00153	CbGpPWpGaD
Bimatoprost—PTGER1—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.62e-05	0.00153	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—NCOR1—urinary bladder cancer	1.58e-05	0.0015	CbGpPWpGaD
Bimatoprost—PTGFR—GPCR downstream signaling—IL2—urinary bladder cancer	1.58e-05	0.00149	CbGpPWpGaD
Bimatoprost—PTGER1—GPCR downstream signaling—IL2—urinary bladder cancer	1.54e-05	0.00146	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—NCOR1—urinary bladder cancer	1.53e-05	0.00144	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—CREBBP—urinary bladder cancer	1.5e-05	0.00142	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling by GPCR—CXCL8—urinary bladder cancer	1.5e-05	0.00142	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—CREBBP—urinary bladder cancer	1.49e-05	0.00141	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—IGF1—urinary bladder cancer	1.47e-05	0.00139	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.47e-05	0.00139	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—EGFR—urinary bladder cancer	1.46e-05	0.00138	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling by GPCR—IL2—urinary bladder cancer	1.43e-05	0.00135	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—TERT—urinary bladder cancer	1.43e-05	0.00135	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling by GPCR—IL2—urinary bladder cancer	1.4e-05	0.00132	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—TERT—urinary bladder cancer	1.4e-05	0.00132	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—KRAS—urinary bladder cancer	1.38e-05	0.00131	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—RHOA—urinary bladder cancer	1.36e-05	0.00128	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—RHOA—urinary bladder cancer	1.35e-05	0.00127	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—TERT—urinary bladder cancer	1.35e-05	0.00127	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—PPARG—urinary bladder cancer	1.31e-05	0.00124	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—FGFR3—urinary bladder cancer	1.31e-05	0.00124	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—FGFR3—urinary bladder cancer	1.28e-05	0.00121	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—ESR1—urinary bladder cancer	1.27e-05	0.0012	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—CREBBP—urinary bladder cancer	1.26e-05	0.00119	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—ERBB2—urinary bladder cancer	1.26e-05	0.00119	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—ERBB2—urinary bladder cancer	1.25e-05	0.00118	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—ESR1—urinary bladder cancer	1.24e-05	0.00118	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—FGFR3—urinary bladder cancer	1.24e-05	0.00117	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—PTGS2—urinary bladder cancer	1.23e-05	0.00116	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—ESR1—urinary bladder cancer	1.2e-05	0.00113	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—CXCL8—urinary bladder cancer	1.18e-05	0.00112	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—HRAS—urinary bladder cancer	1.18e-05	0.00111	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—IL2—urinary bladder cancer	1.13e-05	0.00107	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—CREBBP—urinary bladder cancer	1.11e-05	0.00105	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—CCND1—urinary bladder cancer	1.1e-05	0.00104	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—IGF1—urinary bladder cancer	1.1e-05	0.00104	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling by GPCR—EGFR—urinary bladder cancer	1.1e-05	0.00103	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—CREBBP—urinary bladder cancer	1.09e-05	0.00103	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—IGF1—urinary bladder cancer	1.08e-05	0.00102	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—CDKN1A—urinary bladder cancer	1.08e-05	0.00102	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—PTEN—urinary bladder cancer	1.07e-05	0.00101	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling by GPCR—EGFR—urinary bladder cancer	1.07e-05	0.00101	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—MMP9—urinary bladder cancer	1.07e-05	0.00101	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—CDKN1A—urinary bladder cancer	1.07e-05	0.00101	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—PTEN—urinary bladder cancer	1.06e-05	0.00101	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—CREBBP—urinary bladder cancer	1.05e-05	0.000994	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—IGF1—urinary bladder cancer	1.04e-05	0.000982	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling by GPCR—KRAS—urinary bladder cancer	1.03e-05	0.000977	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—PTGS2—urinary bladder cancer	1.03e-05	0.000974	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—EP300—urinary bladder cancer	1.02e-05	0.000967	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—EP300—urinary bladder cancer	1.02e-05	0.000959	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling by GPCR—KRAS—urinary bladder cancer	1.01e-05	0.000957	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—RHOA—urinary bladder cancer	1.01e-05	0.000952	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—SRC—urinary bladder cancer	9.95e-06	0.00094	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—SRC—urinary bladder cancer	9.87e-06	0.000932	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—RHOA—urinary bladder cancer	9.87e-06	0.000932	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—RHOA—urinary bladder cancer	9.52e-06	0.000899	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—ERBB2—urinary bladder cancer	9.33e-06	0.000882	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—ERBB2—urinary bladder cancer	9.14e-06	0.000863	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—PTEN—urinary bladder cancer	8.99e-06	0.000849	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—MYC—urinary bladder cancer	8.92e-06	0.000843	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—CXCL8—urinary bladder cancer	8.85e-06	0.000836	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—MYC—urinary bladder cancer	8.85e-06	0.000836	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—ERBB2—urinary bladder cancer	8.81e-06	0.000833	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling by GPCR—HRAS—urinary bladder cancer	8.79e-06	0.000831	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—EGFR—urinary bladder cancer	8.72e-06	0.000824	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—CXCL8—urinary bladder cancer	8.66e-06	0.000818	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—EGFR—urinary bladder cancer	8.65e-06	0.000817	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling by GPCR—HRAS—urinary bladder cancer	8.61e-06	0.000813	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—EP300—urinary bladder cancer	8.57e-06	0.00081	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—IL2—urinary bladder cancer	8.46e-06	0.000799	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—CXCL8—urinary bladder cancer	8.36e-06	0.00079	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—IL2—urinary bladder cancer	8.28e-06	0.000782	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—CCND1—urinary bladder cancer	8.25e-06	0.000779	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—KRAS—urinary bladder cancer	8.24e-06	0.000779	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—KRAS—urinary bladder cancer	8.17e-06	0.000772	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—CCND1—urinary bladder cancer	8.07e-06	0.000762	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—MMP9—urinary bladder cancer	8.01e-06	0.000756	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—IL2—urinary bladder cancer	7.99e-06	0.000755	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—CDKN1A—urinary bladder cancer	7.98e-06	0.000753	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—PTEN—urinary bladder cancer	7.96e-06	0.000752	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—MMP9—urinary bladder cancer	7.84e-06	0.00074	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—CDKN1A—urinary bladder cancer	7.81e-06	0.000738	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—PTEN—urinary bladder cancer	7.79e-06	0.000736	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—CCND1—urinary bladder cancer	7.79e-06	0.000736	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—EP300—urinary bladder cancer	7.59e-06	0.000717	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—MMP9—urinary bladder cancer	7.56e-06	0.000714	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—CDKN1A—urinary bladder cancer	7.53e-06	0.000712	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—PTEN—urinary bladder cancer	7.52e-06	0.00071	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—EP300—urinary bladder cancer	7.43e-06	0.000702	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—SRC—urinary bladder cancer	7.38e-06	0.000697	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—TP53—urinary bladder cancer	7.26e-06	0.000686	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—SRC—urinary bladder cancer	7.22e-06	0.000682	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—EP300—urinary bladder cancer	7.17e-06	0.000677	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—HRAS—urinary bladder cancer	7.01e-06	0.000662	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—SRC—urinary bladder cancer	6.97e-06	0.000658	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—HRAS—urinary bladder cancer	6.95e-06	0.000656	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—MYC—urinary bladder cancer	6.61e-06	0.000625	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—MYC—urinary bladder cancer	6.47e-06	0.000612	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—EGFR—urinary bladder cancer	6.47e-06	0.000611	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—EGFR—urinary bladder cancer	6.33e-06	0.000598	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—MYC—urinary bladder cancer	6.25e-06	0.00059	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—KRAS—urinary bladder cancer	6.11e-06	0.000577	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—EGFR—urinary bladder cancer	6.11e-06	0.000577	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—KRAS—urinary bladder cancer	5.98e-06	0.000565	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—KRAS—urinary bladder cancer	5.77e-06	0.000545	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—TP53—urinary bladder cancer	5.43e-06	0.000513	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—TP53—urinary bladder cancer	5.32e-06	0.000502	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—HRAS—urinary bladder cancer	5.19e-06	0.000491	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—TP53—urinary bladder cancer	5.13e-06	0.000485	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—HRAS—urinary bladder cancer	5.08e-06	0.00048	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—HRAS—urinary bladder cancer	4.91e-06	0.000463	CbGpPWpGaD
